| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -3.6 | -5.2 |
| Net income | -3.6 | -5.1 |
| EPS (diluted, $ a share) | $-1.47 | $-35.25 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NYSE: CLDI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Calidi Biotherapeutics, Inc.: key numbers
- Share price
- $0.6023Close, Nov 16
- Market cap
- $2.08M
- Shares outstanding
- 3.45MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Calidi Biotherapeutics, Inc.
All →Calidi Biotherapeutics Financial Results
Calidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the prior year period. The company highlighted preclinical progress for its CLD-401 program and implemented a restructuring plan on November 6, 2026, to reduce headcount and save $3 million annually. During the quarter, the company also raised $1.2 million through an at-the-market offering to extend its cash runway.
- Term
- Q3 2026
“Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine. In particular, CLD-401 demonstrated remarkable anti-tumor activity with systemic administration in syngeneic tumor models and continues to progress towards the clinic.”
Eric Poma, Ph.D., Calidi Biotherapeutics CEO
Calidi Biotherapeutics Nasdaq/NYSE Compliance Notice
Calidi Biotherapeutics received a deficiency notice from NYSE American for failing to maintain the minimum stockholders' equity requirement of $4.0 million. The company reported stockholders' equity of $3.1 million as of June 30, 2026, and has until October 21, 2026, to submit a plan to regain compliance by March 21, 2028.
- Counterparty
- NYSE American LLC
- Term
- through March 21, 2028
Calidi Biotherapeutics Capital Raise of $1.2M
Calidi Biotherapeutics entered into a stock purchase agreement to sell 1,025,640 shares of common stock in a registered direct offering at $1.17 per share. The offering generated gross proceeds of approximately $1.2 million, which the company intends to use for working capital and general corporate purposes.
- Value
- $1.2M